Completed PHASE3 INTERVENTIONAL 2-arm NCT06952231

Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus

Comparison of Effect of Sitagliptin and Empagliflozin in Combination With Metformin on High-Sensitivity C-Reactive Protein Levels in Patients With Type 2 Diabetes Mellitus

Sponsor: University of Lahore

Conditions Diabetes Mellitus

Interventions Empagliflozin + Metformin Sitagliptin + Metformin

Updated 2 times since 2025 Last updated: Apr 26, 2025 Started: May 21, 2024 Primary completion: Dec 10, 2024 Completion: Jan 5, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetes Mellitus, this trial is completed. The trial is conducted by University of Lahore and has accumulated 2 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Nov 2025 — Present [monthly]

Completed PHASE3
May 2025 — Nov 2025 [monthly]

Completed PHASE3

First recorded

May 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Lahore
University of Lahore Hospital (ULH)

Data source: University of Lahore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lahore, Pakistan